Octuple-COVID-19-vaccinated politician dies from COVID-19 at 75

On September 2 of 2020, Vladimir Zhirinovsky, the leader of the Liberal Democratic Party (LDPR) of Russia, received his first dose of COVID-19 vaccine - as a participant of Gam-COVID-Vac (Sputnik V) clinical trials. 3 weeks later he got the second dose with no side effects. 

Sputnik V (Спутник V) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health. Gam-COVID-Vac was initially approved for distribution in Russia and then in at least 59 other countries on the preliminary results of Phase I–II studies eventually published on 4 September 2020. Both doses of Sputnik V contain non-replicating viral vectors. The first component uses adenovirus type 26 (AD26), and the second — which a person receives 21 days later — contains adenovirus type 5 (AD5). 

Several of the presently approved vaccines against SARS-Coronavirus-2 (AstraZeneca/Oxford University, Johnson & Johnson's Janssen COVID-19 Vaccine, and Sputnik V) are based on adenovirus DNA vectors as carriers for the genetic information for the SARS-COV-2 spike glycoprotein.

Since antibody titers decline 3-month post-vaccination, In December 2020, Zhirinovsky received Sputnik Light, essentially the 3rd booster dose of the Sputnik V vaccine. The Sputnik Light vaccine is made from Ad26, which is the first part of the Sputnik V vaccine. Sputnik Light is authorized for use in Russia as a single-dose vaccine. Johnson and Johnson’s single-dose vaccine is also based on human adenovirus serotype number 26 (rAd26)

Zhirinovsky received the 4th dose in form of a nasal spray - then experimental but recently authorized for use by Russian Department of Health. 

7 months later, Zhirinovsky received the 5th and later the 6th doses of another COVID-19 vaccine - CoviVac (КовиВак) developed by the Chumakov Center. 4 months after that, in December 2021, he received his 7th and 8th doses of the same CoviVac vaccine.  


CoviVac is an inactivated virus-based COVID-19 vaccine. It was developed with a more traditional technology similar to the inactivated polio vaccine, Hepatitis A and rabies. Initially, a sample of SARS-CoV-2 strain AYDAR-1 (GISAID EPI_ISL_428851) was isolated from a nasopharyngeal swab sample of a COVID-19 patient, replcated (vero cell), deactivated and mixed with an aluminium-based adjuvant.

Sinovac, Sinopharm, and Bharat Biotech developed their COVID-19 vaccines using similar inactivated vaccines technology. 

On February 2, 2022, a little over a month after receiving his 8-th dose of Coronavirus vaccine, Zhirinovsky was hospitalized in critical condition with COVID-19. On February 9th, he was placed on ventilator in a medically induced coma. In March, he was undergoing treatment for COVID-19 complications such as sepsis and respiratory failure. 

Today, on April 6th, 2022, state Duma speaker Vyacheslav Volodin announced that Zhirinovsky died after "a serious and prolonged illness."


REFERENCES

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020 Sep 26;396(10255):887-97.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021 Feb 20;397(10275):671-81.

Kozlovskaya LI, Piniaeva AN, Ignatyev GM, Gordeychuk IV, Volok VP, Rogova YV, Shishova AA, Kovpak AA, Ivin YY, Antonova LP, Mefyod KM. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerging microbes & infections. 2021 Jan 1;10(1):1790-806.

Kozlovskaya L, Piniaeva A, Ignatyev G, Selivanov A, Shishova A, Kovpak A, Gordeychuk I, Ivin Y, Berestovskaya A, Prokhortchouk E, Protsenko D. Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak. International Journal of Infectious Diseases. 2020 Oct 1;99:40-6.

Жириновский, Владимир Вольфович — Википедия (wikipedia.org)

Что стало причиной смерти Владимира Жириновского? | В России | Политика | Аргументы и Факты (aif.ru)

Умер Владимир Жириновский // НТВ.Ru (ntv.ru)


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more